The global humanized mouse model market to grow at a CAGR of 9.84% during the period 2017-2021.
Global Humanized Mouse Model Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
One trend in the market is increasing production of mABs. mABs are important tools for molecular biology research. They provide essential information about proteins that influence cell activity as they have a strong affinity toward such proteins due to their molecular structure. They are important for cancer diagnosis and treatment as the specificity of these chemical entities allows their binding to cancerous cells in conjunction with a cytotoxic agent, which destroys the cancerous cells without affecting other cells.
According to the report, one driver in the market is increasing use of mice-based research. Rats and mice are ideal models for biotechnology and related medical research. This is because they offer certain genetic and physiological advantages when compared with other species, which makes them ideal replacements for humans. Rats, mice, and humans share approximately 95% of their genetic makeup. Hence, their anatomical and physical functions can be studied in greater detail. This information can be applied to human research to develop advanced therapies.
- Horizon Discovery
- Taconic Biosciences
- Jackson Laboratory
Other Prominent Vendors
- Champion Oncology
- Crown Bioscience
- HuMurine Technologies
- inGenious Targeting Laboratory
- TRANS GENIC
Key Topics Covered:
PART 01: Executive summary
PART 02: Scope of the report
PART 03: Research Methodology
PART 04: Introduction
PART 05: Market landscape
PART 06: Segmentation by product type
PART 07: Segmentation by end-user
PART 08: Segmentation by geography
PART 09: Decision framework
PART 10: Drivers and challenges
PART 11: Market trends
PART 12: Vendor landscape
PART 13: Key vendor analysis